It looks like this podcast has ended some time ago. This means that no new episodes have been added some time ago. If you're the host of this podcast, you can check whether your RSS file is reachable for podcast clients.
Endocrinology @Point of Care Podcasts
by @Point of CareOur @Point of Care Endocrinology Podcasts have healthcare experts discussing and providing information related to endocrinology diagnosis, treatment, management, and other important information.
Copyright: Copyright 2021 At Point of Care, LLC. All rights reserved.
Episodes
S1E6 - SGLT-2 Inhibitors Morning Commute: A Clinical Pathway for Action
24m · PublishedS1E5 - SGLT-2 Inhibitors Morning Commute: The Heart Failure Connection
24m · PublishedVisit http://morningcommutepodcast.com/SGLT2inhibitors5 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit. In this episode Dr. James Januzzi and Dr. Silvio Inzucchi discuss how sodium-glucose cotransporter 2 (SGLT-2) inhibitors evolved from treatments for type 2 diabetes mellitus (T2DM) to key treatments for patients with heart failure. Drs. Januzzi and Inzucchi look at the pivotal trials that thrust these treatments into the heart failure treatment limelight.
S1E4 - SGLT-2 Inhibitors Morning Commute: Widening Benefit
25m · PublishedVisit http://morningcommutepodcast.com/SGLT2inhibitors4 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit. In this episode Dr. James Januzzi and Dr. Silvio Inzucchi will discuss SGLT-2 inhibition in cardiovascular risk reduction by taking a look at some of the pivotal clinical trial data.
S1E3 - SGLT-2 Inhibitors Morning Commute: Optimizing Benefit in CKD Management
25m · PublishedVisit http://morningcommutepodcast.com/SGLT2inhibitors3 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit. In this episode, our experts will focus on chronic kidney disease (CKD) in patients with or without diabetes and treatment with sodium-glucose cotransporter 2 (SGLT-2) inhibitors. The bottom line is, how should these treatments be incorporated into clinical practice?
S1E2 - SGLT-2 Inhibitors Morning Commute: CKD Benefit in Diabetic and Non-Diabetic Patients
24m · PublishedVisit http://morningcommutepodcast.com/SGLT2inhibitors2 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit. In this episode, our experts will discuss clinical trial data that look at new directions for the use of sodium-glucose cotransporter 2 (SGLT-2) inhibitors, particularly how they benefit patients with chronic kidney disease (CKD).
S1E1 - SGLT-2 Inhibitors Morning Commute: A Mechanistic Explanation of Renal Benefit
26m · PublishedVisit http://morningcommutepodcast.com/SGLT2inhibitors1 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit. In this episode, our experts will be discussing sodium-glucose cotransporter 2 (SGLT-2) inhibitors and their role beyond glycemic control. What are the mechanisms and renal benefit of SGLT-2 inhibitors?
Endocrinology @Point of Care Podcasts has 6 episodes in total of non- explicit content. Total playtime is 2:29:38. The language of the podcast is English. This podcast has been added on November 27th 2022. It might contain more episodes than the ones shown here. It was last updated on April 3rd, 2024 09:11.